Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
zydus
10 Tablets in Strip
Imatinib
Keep in cold place
Delivering To:
Overview
Imat 400 mg tablet is used for the treatment of several cancers. It is commonly used to treat gastrointestinal stromal tumors and blood cancers (chronic myeloid leukemia and acute lymphocytic leukemia). It inhibits or prevents the specific proteins that play an important role in the growth and spread of cancer cells. Certain types of skin cancers or tumours, dermatofibrosarcoma protuberans, and a type of bone marrow condition called aggressive systemic mastocytosis can also be treated with Imat 400 mg Tablet. Consult your doctor before taking any other medication, as it may interfere with Imat 400 mg Tablet and reduce the effectiveness of the medicine. During pregnancy and breastfeeding, you are recommended not to take Imat 400 mg Tablet. |
Blood cancer, bone marrow cancer, Gastrointestinal stromal tumor, and skin cancer.
Blood cancer (Chronic myeloid leukaemia)
Gastrointestinal stromal tumour
Treatment of Cancer
The human body reacts differently to Imat 400 mg Tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Imat 400 mg Tablet are mentioned below:
High risk of infection
Vomiting
Weakness
Nausea
Fatigue
Fever
Decreased blood cells (red cells, white cells, and platelets)
Diarrhea
Cough
Take the dose of Imat 400 mg Tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. The Imat 400 mg Tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole.
Imat 400 mg Tablet is an anti-cancer medication that inhibits the proliferation of BCR-ABL tyrosine kinase, a protein enzyme. This enzyme helps cancer cells multiply and is responsible for the abnormal proliferation of cancer cells. Imat 400 mg Tablet also induces apoptosis (programmed cell death) in BCR-ABL positive cells (cancer cells).
Alcohol
unsafe
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Imat 400 mg Tablet. Consult your doctor for further information.
Pregnancy
consult your doctor
Imat 400 mg Tablet may be considered unsafe during pregnancy. Please consult your doctor in such a condition. According to some research data, taking Imat 400 mg Tablet during pregnancy has shown harmful effects on the developing baby.
Breast Feeding
consult your doctor
Imat 400 mg Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor before taking Imat 400 mg Tablet while breastfeeding, as there are chances that it may pass to the developing baby through the breast milk of the mother.
Driving
danger
It is advisable not to drive or operate heavy machinery after taking Imat 400 mg Tablet, as you may feel dizzy.
Kidney
precaution
Share your medical history with your healthcare expert in case of kidney disease before taking Imat 400 mg Tablet. Patients with renal impairment must be careful while taking Imat 400 mg Tablet. They may require adjustment in the dose.
Liver
precaution
Inform your doctor before starting Imat 400 mg Tablet. if you have liver disease, avoid any serious side effects. Patients with hepatic impairment must be careful while taking Imat 400 mg Tablet. They may require adjustment in the dose.
Yes, it is advised to take Imat 400 mg Tablet with water and food so as to prevent irritation in the food pipe and stomach. If you face trouble in swallowing the tablet, then dissolve the tablet in a glass of water or apple juice (approximately 50 ml for a 100 mg tablet and 200 ml for a 400 mg tablet).
Memory impairments have been reported in a few patients. Consult your doctor if you face problems with concentration, loss of memory, or are confused.
Time and dose are decided by your doctor. An Imat 400mg tablet should be taken at the same time, usually with a meal and a large glass of water to avoid stomach problems.
No, children below 18 years of age are not advised to take this medicine as it results in severe complications.
No, it is advised to avoid taking this medicine if you have serious kidney problems. Consult the doctor before taking this medication.
It is advisable not to drive or operate heavy machinery as you may feel dizzy after taking Imat 400 mg Tablet.
It is not safe to use this medicine during pregnancy as it causes harmful effects in the developing baby.
The Imat 400 mg Tablet may take days to a week to work properly. It depends on patients’ medical history, age, health condition, and the body's response to the treatment.
If you take extra doses of Imat 400 mg Tablet, then you should immediately go to the hospital emergency room or call your healthcare provider right away.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
I. Iacobucci et al. (2023). Five-year follow-up results of imatinib 400 mg in late chronic phase chronic myeloid leukemia (CML) patients. J Clin Oncol 25, 7041-7041.
Parrillo-Campiglia S, Ercoli MC, Umpierrez O, Rodríguez P, Márquez S, Guarneri C, Estevez-Parrillo FT, Laurenz M, Estevez-Carrizo FE. (2024). Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: a randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers. Clin Ther. 31(10):2224-32.
Radich JP, Kopecky KJ, Appelbaum FR, Kamel-Reid S, Stock W, Malnassy G, Paietta E, Wadleigh M, Larson RA, Emanuel P, Tallman M, Lipton J, Turner AR, Deininger M, Druker BJ. (2024). A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood. 120(19):3898-905.
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. (2025). Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 362(24):2260-70.
Midha KK, Rawson MJ, Hubbard JW. (2025). The bioequivalence of highly variable drugs and drug products. Int J Clin Pharmacol Ther. 43(10):485-98.
Druker BJ,Guilhot F,O'Brien SG, et al. (2024). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 355: 2408-2417.
O'Brien SG,Guilhot F,Larson RA, et al. (2023). Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. N Engl J 348: 994-1004.
zydus
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.